Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Unraveling The Clinical Impact Of Differential Dna Methylation In Pdac: A Systematic Review.
  1. Home
  3. Unraveling The Clinical Impact Of Differential Dna Methylation In Pdac: A Systematic Review.

Related Concept Videos

Related Experiment Videos

Unraveling the clinical impact of differential DNA methylation in PDAC: A systematic review.

Julia Adriana Kasmirski1, Raj Roy1, Christopher Wu1

  • 1Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.

European Journal of Cancer (Oxford, England : 1990)
|March 28, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

DNA methylation in pancreatic ductal adenocarcinoma (PDAC) impacts prognosis. Hypermethylation of SFRP1 and NPTX2 genes correlates with poor outcomes, suggesting potential therapeutic targets for this aggressive cancer.

Keywords:
EpigeneticsMethylationPDACPancreatic cancer

Related Experiment Videos

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) presents a significant challenge due to high mortality rates.
  • Its poor prognosis is linked to genetic variability and epigenetic modifications like DNA methylation.
  • A comprehensive understanding of DNA methylation's clinical impact in PDAC is lacking.

Purpose of the Study:

  • To systematically review the literature on the clinical impact of DNA methylation in pancreatic ductal adenocarcinoma.
  • To identify specific genes or CpG sites associated with PDAC diagnosis, prognosis, or survival.

Main Methods:

  • A systematic literature review was conducted following PRISMA guidelines.
  • Searches were performed across multiple databases including CINAHL, Cochrane, Embase, Web of Science, Ovid Medline, and Google Scholar.
  • Studies involving PDAC patients with data on gene/CpG site methylation affecting outcomes were included.

Main Results:

  • Out of 2402 initial articles, 19 studies met the inclusion criteria.
  • SFRP1 and NPTX2 were the most frequently identified genes implicated in PDAC pathogenesis.
  • Hypermethylation of SFRP1 and NPTX2 was associated with a poorer prognosis in PDAC patients.

Conclusions:

  • Epigenetic alterations, particularly DNA methylation, play a role in PDAC.
  • Methylation of specific genes like SFRP1 and NPTX2 may serve as prognostic markers and potential therapeutic targets.
  • Personalized epigenetic analysis could guide future PDAC treatment strategies.